100% agree it has been the big piece missing in the last 3 years. IF the brain Mets data, that had a 100% response rate on first 10 patients, continued to next 10-20 it is huge news. If DIPG data had come out in July, like they promised twice and is close to the compassionate use patients Dr. Dunn reports on, that too would have moved the needle. The GBM data may need a deeper dive beyond methylation status, new vs recurrent to add in PI3K/genomics to tease out a subpopulation that responds. Getting an NDA on even a subpopulation of GBM would still be huge news.
KZA Price at posting:
6.1¢ Sentiment: None Disclosure: Held
